G20.B1

🧬 ICD-10-CM G20.B1 — Parkinson’s Disease With Dyskinesia, Without Mention of Fluctuations

Billable Code Confirmed

ICD-10-CM G20.B1 is a valid, billable 5-character alphanumeric ICD-10-CM code for FY2026. All five characters are present: G20 (category — Parkinson’s Disease) + .B (with dyskinesia) + 1 (without mention of fluctuations/OFF episodes). No 7th character is required. Introduced effective October 1, 2023 (FY2024) as part of the G20 subcategory expansion replacing the retired single G20 code.

Non-Billable Parent Codes — Never Submit These

• ❌ G20 — Retired 3-character code; non-billable since FY2024; generates a coding specificity rejection
• ❌ G20.B — 4-character header — non-billable; missing fluctuation specifier

Always submit G20.B1 (all 5 characters) when Parkinson’s disease with dyskinesia AND without documented motor fluctuations or OFF episodes is the diagnosis. Never default to the retired bare G20 or the non-billable G20.B header.

Critical AHA Coding Clinic Guidance — Dyskinesia ≠ Tremor

G20.B1 and the entire G20.B subcategory should ONLY be assigned when dyskinesia associated with Parkinson’s disease is specifically documented by the provider. Per AHA Coding Clinic (Q1 2024) guidance:

“Codes in subcategory G20.B-, Parkinson’s disease with dyskinesia, should only be assigned when dyskinesia associated with Parkinson’s disease is specifically documented by the provider.”

Tremor — the characteristic rest tremor of Parkinson’s disease — is NOT dyskinesia. Rest tremor is a cardinal PD motor symptom present from diagnosis. Dyskinesia is a distinct, separate phenomenon: involuntary, purposeless writhing, choreiform, or choreoathetoid movements that are a pharmacological complication of long-term dopaminergic (levodopa) therapy. Coders must NEVER infer dyskinesia from tremor documentation, and must NEVER assign G20.B1 simply because the patient has tremor or shaking. The physician must explicitly document “dyskinesia,” “levodopa-induced dyskinesia,” “LID,” “involuntary movements,” or equivalent physician-level language.

Code Classification

ICD-10-CM Diagnosis Code — Etiology code. G20.B1 sequences FIRST when Parkinson’s disease dementia is also coded — the F02.x dementia codes are mandatory manifestation codes that always sequence second. For associated inpatient procedure coding, see the ICD-10-PCS Crosswalk section below.

---

🔍 Code Description

ICD-10-CM G20.B1 classifies idiopathic Parkinson’s disease at the stage characterized by the presence of levodopa-induced dyskinesia (LID) — involuntary, purposeless motor movements arising as a pharmacological complication of long-term dopaminergic therapy — in the absence of documented motor fluctuations (wearing-off / OFF episodes).

Levodopa-induced dyskinesia (LID) develops when long-term pulsatile levodopa stimulation produces progressive dopamine receptor hypersensitization in the striatum — particularly at D1 receptors in the direct pathway — causing abnormal cortico-basal ganglia-thalamo-cortical circuit activity that generates involuntary hyperkinetic movements. LID affects approximately 30-40% of PD patients after 4-6 years of levodopa therapy and up to 90% after 9-10 years, making it one of the most prevalent and disabling long-term complications of Parkinson’s disease treatment.

The “without mention of fluctuations” qualifier in G20.B1 specifies that while dyskinesia is present, there is no documented wearing-off, OFF episodes, or motor fluctuation pattern — the levodopa response is otherwise consistent and reliable between doses, but dyskinesia emerges at or near the peak of levodopa effect. This represents a pharmacologically distinct scenario from G20.B2 (both dyskinesia AND fluctuations), where both complications coexist simultaneously. G20.B1 may reflect an earlier phase of the levodopa complication arc — dyskinesia appearing before wearing-off develops — or a clinical situation where dyskinesia is the predominant complication while dose-to-dose consistency is maintained.

---

🌳 Code Tree / Hierarchy

G20-G26 Extrapyramidal and Movement Disorders  
│  
├── G20 — Parkinson's Disease ❌ Non-billable (retired as of FY2024)  
│ │ [Excludes1: dementia with Parkinsonism (G31.83)]  
│ │ [Excludes1: drug induced dystonia (G24.0-) at G20.B subcategory level]  
│ │ [Use additional code for dementia]  
│ │  
│ ├── G20.A — PD Without Dyskinesia ❌ Non-billable header  
│ │ ├── G20.A1 — Without dyskinesia, without mention of fluctuations ✅ Billable  
│ │ └── G20.A2 — Without dyskinesia, with fluctuations ✅ Billable  
│ │  
│ ├── G20.B — PD With Dyskinesia ❌ Non-billable header  
│ │ │ [Excludes1: drug induced dystonia (G24.0-)]  
│ │ ├── G20.B1 — With dyskinesia, WITHOUT mention of fluctuations ◀ THIS CODE ✅ Billable  
│ │ │ [= Dyskinesia present; no wearing-off/OFF episodes documented]  
│ │ └── G20.B2 — With dyskinesia, WITH fluctuations ✅ Billable  
│ │ [= Both dyskinesia AND wearing-off/OFF — most advanced motor complication stage]  
│ │  
│ └── G20.C — Parkinsonism, unspecified ✅ Billable  
│ [Use ONLY when idiopathic vs. secondary undetermined]  
│  
├── G21 — Secondary Parkinsonism ← EXCLUDES1 from G20 — separate code family  
│ ├── G21.11 — Neuroleptic induced Parkinsonism ✅ Billable  
│ ├── G21.19 — Other drug induced secondary Parkinsonism ✅ Billable  
│ ├── G21.3 — Postencephalitic Parkinsonism ✅ Billable  
│ ├── G21.4 — Vascular Parkinsonism ✅ Billable  
│ ├── G21.8 — Other secondary Parkinsonism ✅ Billable  
│ └── G21.9 — Secondary Parkinsonism, unspecified ✅ Billable  
│  
└── G24 — Dystonia — Excludes1 from G20.B subcategory  
├── G24.01 — Drug induced subacute dyskinesia (tardive dyskinesia) ✅ Billable  
└── G24.02 — Drug induced acute dystonia ✅ Billable

G20.B1 → G20.B2 Upgrade: When Fluctuations Emerge

G20.B1 applies only as long as motor fluctuations (wearing-off, OFF episodes) remain absent. Once wearing-off or OFF episodes emerge alongside existing dyskinesia, the code must be upgraded to G20.B2 (both dyskinesia AND fluctuations). Query the physician at every visit: “Does the patient experience wearing-off or OFF periods between doses?” A “yes” in the context of G20.B1-stage dyskinesia = code change to G20.B2.

---

✅ Includes

The following clinical terms and scenarios map to G20.B1 when idiopathic Parkinson’s disease is confirmed with specifically documented dyskinesia and without documented motor fluctuations:

• Parkinson’s disease with levodopa-induced dyskinesia (LID), no wearing-off documented
• Parkinson’s disease with peak-dose dyskinesia, no OFF episodes
• Parkinson’s disease with diphasic dyskinesia, no motor fluctuations documented
• Parkinson’s disease with involuntary choreiform/choreoathetoid movements, consistent levodopa response
• PD with dyskinesia, stable between-dose intervals, no wearing-off

Physician Must Specifically Document Dyskinesia

Per AHA Coding Clinic Q1 2024: “Tremor” alone does not map to G20.B — tremor is a cardinal PD symptom present from disease onset. G20.B1 requires the physician to explicitly document dyskinesia, levodopa-induced dyskinesia, involuntary movements, LID, or equivalent. Do not infer dyskinesia from phrases like “shaking,” “trembling,” or “tremor” — these map to the G20.A subcategory (no dyskinesia) unless dyskinesia is also separately and specifically documented.

---

❌ Excludes

Excludes 1 — Cannot Be Coded Simultaneously with G20.B1

Code	Description	Note
G24.01	Drug induced subacute dyskinesia (tardive dyskinesia)	Critical Excludes 1 at the G20.B subcategory level — drug-induced dystonia/tardive dyskinesia from neuroleptic agents is a separate movement disorder coded to G24.01; cannot coexist with G20.B1. The distinction: levodopa-induced dyskinesia in idiopathic PD = G20.B1; neuroleptic/antipsychotic-induced tardive dyskinesia = G24.01. If a PD patient on both levodopa AND an antipsychotic develops involuntary movements, the physician must document the clinical attribution (levodopa-induced vs. tardive) before code assignment
G24.02	Drug induced acute dystonia	Excludes 1 from G20.B — acute dystonic reactions from drugs are coded to G24.02, not G20.B1
G21.11	Neuroleptic induced Parkinsonism	Mutually exclusive with all G20 idiopathic PD codes
G21.19	Other drug induced secondary Parkinsonism	Mutually exclusive
G21.3	Postencephalitic Parkinsonism	Mutually exclusive
G21.4	Vascular Parkinsonism	Mutually exclusive
G21.8	Other secondary Parkinsonism	Mutually exclusive
G21.9	Secondary Parkinsonism, unspecified	Mutually exclusive

The G24.01 / G20.B1 Distinction Is the Most Critical Excludes 1 for G20.B

The most clinically consequential Excludes 1 boundary at the G20.B subcategory level is G24.01 (drug-induced subacute dyskinesia / tardive dyskinesia) vs. G20.B1 (Parkinson’s disease with levodopa-induced dyskinesia). These are:

• Distinct movement disorders with different pharmacological mechanisms
• Mutually exclusive ICD-10-CM codes — they cannot be assigned simultaneously
• Both require specific physician documentation of the causative agent and clinical attribution

When a patient with Parkinson’s disease is ALSO on a dopamine-blocking agent (antipsychotic, metoclopramide, prochlorperazine) and develops involuntary movements, the physician must document whether the dyskinesia is levodopa-induced (G20.B1) or drug-induced tardive dyskinesia (G24.01) — a CDI query is mandatory when attribution is ambiguous.

Excludes 2 — May Be Coded in Addition if Separately Present

Code	Description	Note
G31.83	Dementia with Lewy bodies	Excludes 2 from G20 category — may be coded alongside G20.B1 if DLB is distinctly documented per the 1-year rule (DLB = dementia onset within 1 year of motor onset; PDD = dementia onset >1 year after established motor PD)

Off-Dystonia — A Special Dyskinesia Subtype That May Coexist

Off-period dystonia (painful sustained muscle contractions occurring in the OFF state, often early morning before first levodopa dose) is a distinct LID subtype. Some sources classify off-dystonia separately from the “dyskinesia” that defines G20.B, as it occurs during LOW levodopa levels (OFF state) rather than peak-dose. Per the G20 tabular instruction, the G20.B codes capture dyskinesia as a documented complication — physician documentation of “off-dystonia” should prompt a coding query to clarify whether it represents a dyskinesia-type complication (→ G20.B1 territory) or an OFF-state motor phenomenon (→ consider G20.A2 or G20.B2 depending on fluctuation status). When in doubt, a physician query is the appropriate compliance-preserving action.

---

📋 Clinical Overview

The Three Types of Levodopa-Induced Dyskinesia

G20.B1 captures all documented LID subtypes — the clinical distinction between types is important for treatment planning but does not affect code selection (all three remain G20.B1 when fluctuations are absent).

LID Type	Temporal Pattern	Clinical Appearance	Levodopa Level	Treatment Focus
Peak-dose dyskinesia	At maximum levodopa effect (peak plasma concentration)	Choreiform, choreoathetoid, or ballistic movements; most often affecting trunk, neck, limbs; typically not painful	High (ON state)	Reduce levodopa dose; amantadine ER (GOCOVRI); DBS
Diphasic dyskinesia	At onset AND offset of levodopa effect (“dyskinesia-improvement-dyskinesia” pattern)	Repetitive, stereotyped, slow oscillatory lower limb movements; often dystonic quality	Ascending AND descending plasma levels	More difficult to treat; dopamine agonist adjustment; apomorphine; DBS
Off-period dystonia	During OFF state — low levodopa levels; often early morning	Painful sustained muscle contractions; foot/ankle most common; often first symptom of LID spectrum	Low (OFF state)	Extend levodopa coverage; bedtime ER formulations; DBS

Peak-Dose Dyskinesia Is Most Common and Best Recognized

Peak-dose dyskinesia accounts for the majority of documented LID and is what most physicians mean when they document “dyskinesia” in PD — it produces the characteristic choreiform writhing at peak medication effect that patients describe as “wiggling” or “squirming” and that is often visible during the examination. Peak-dose LID at the G20.B1 stage (no fluctuations yet) is the primary clinical trigger for amantadine initiation and DBS candidacy evaluation.

Pathophysiology of Levodopa-Induced Dyskinesia

The development of LID (G20.B stage) follows progressive dopaminergic terminal depletion beyond what was present at the G20.A stage. As more nigral neurons are lost, the remaining terminals cannot adequately buffer the pulsatile dopamine surges produced by each oral levodopa dose — exogenous levodopa produces high peak striatal dopamine concentrations followed by troughs that mirror the plasma pharmacokinetic curve. This pulsatile receptor stimulation drives maladaptive synaptic plasticity at striatal D1 dopamine receptors: receptor hypersensitization, upregulation of deltaFosB and downstream transcription factors, and aberrant ERK signaling produce abnormal basal ganglia output patterns that manifest as LID. The direct pathway (striatum → GPi/SNr → thalamus → cortex) becomes pathologically overactivated at peak-dose, driving the choreiform movements characteristic of peak-dose LID. GPi deep brain stimulation reduces LID by directly suppressing pathological GPi output — making DBS the most effective treatment for disabling dyskinesia.

Treatment Landscape at G20.B1 Stage

Treatment	Mechanism	Notes
Amantadine immediate release	NMDA receptor antagonist; reduces dyskinesia amplitude; also has dopaminergic activity	First-line for LID; available generically; twice to three times daily dosing
Amantadine ER (GOCOVRI 274 mg)	Extended-release amantadine; bedtime dosing produces higher morning plasma levels when LID is worst	FDA-approved specifically for LID in PD; Phase III trials (EASE LID, EASE LID 3) demonstrated significant LID reduction; the ONLY FDA-approved medication specifically for LID
Levodopa dose reduction	Reduce peak plasma levodopa to reduce peak-dose dyskinesia	Risks increasing OFF time — may not be feasible if wearing-off develops
Smaller, more frequent levodopa doses	Reduce concentration peaks while maintaining total daily dose	Reduces pulsatility; inconvenient but effective for peak-dose LID
Dopamine agonist substitution	Longer-acting dopamine agonists provide more tonic stimulation than pulsatile levodopa	Ropinirole, pramipexole, rotigotine patch — reduce LID by reducing levodopa requirement
Deep Brain Stimulation (DBS)	GPi or STN stimulation reduces LID by modulating pathological basal ganglia output	Most effective treatment for disabling dyskinesia; DBS is the definitive advanced therapy at G20.B1/B2 stage
Levodopa-carbidopa intestinal gel (LCIG/CLES)	Continuous intrajejunal infusion eliminates pulsatile levodopa delivery	Reduces LID by providing constant drug levels; requires PEG/J tube

Documentation Requirements

For accurate assignment of G20.B1, physician documentation must include:

1. Explicit Parkinson’s disease diagnosis — “Parkinson’s disease,” “idiopathic Parkinson’s disease,” or “PD”
2. Explicit dyskinesia documentation — “dyskinesia,” “levodopa-induced dyskinesia,” “LID,” “involuntary movements,” “choreiform movements” — NOT “tremor” alone; per AHA Coding Clinic Q1 2024, G20.B codes require specific physician documentation of dyskinesia
3. Absence of fluctuations — no documented wearing-off, OFF episodes, or ON-OFF phenomenon; if fluctuations are present → G20.B2
4. Confirmation of idiopathic etiology — no drug-induced or secondary Parkinsonism
5. Attribution of dyskinesia to levodopa/dopaminergic therapy — important to distinguish from tardive dyskinesia (G24.01), especially when patient is also on dopamine-blocking agents
6. Dementia status — document severity and behavioral disturbance type when present for the mandatory F02.x code pair

---

💰 HCC Risk Adjustment (CMS-HCC v28)

Field	Detail
CMS-HCC Model Version	v28 (100% Implementation FY2026)
HCC Assignment	✅ Mapped — HCC 155
HCC Category Name	Parkinson’s Disease and Huntington’s Disease
RAF Coefficient (Community Non-Dual Aged)	~0.372
G20 Subcode Differentiation	G20.B1 maps to same HCC 155 as G20.A1/A2/B2 — dyskinesia/fluctuation subcode does not differentiate HCC tier
RxHCC Assignment	Review current RxHCC mapping tables

G20.B1 maps to CMS-HCC v28 HCC 155 (Parkinson’s Disease and Huntington’s Disease), providing a RAF coefficient of approximately 0.372 for community non-dual aged beneficiaries. All four G20 idiopathic PD subcodes map to the same HCC tier — but the G20.B stage is clinically correlated with higher overall comorbidity burden and expanded compound HCC opportunities.

Compound HCC Opportunities at G20.B1 — Dyskinesia Stage Is Higher Burden

At the G20.B1 dyskinesia stage, the following RAF-bearing comorbidities are increasingly prevalent and must be actively reviewed at every encounter:

• Parkinson’s disease dementia (F02.80 through F02.C4) → HCC 125/126/127; the highest-impact stacked HCC; query severity and disturbance type at every visit
• Major depressive disorder (F32.9, F33.9) — prevalent neuropsychiatric PD comorbidity; review HCC mapping
• Dysphagia (R13.19) → drives aspiration precautions; increasingly prevalent
• aspiration pneumonia (J69.0) → MCC; more likely at dyskinesia stage due to dysphagia progression
• malnutrition (E43, E44.0) → review HCC mapping; dyskinesia can cause significant caloric expenditure and weight loss
• Orthostatic hypotension / autonomic dysfunction (G90.3) → prevalent at advanced PD stages

Malnutrition in particular is underrecognized at the G20.B stage — the energy expenditure from constant involuntary movements can produce clinically significant weight loss requiring physician documentation and nutritional status coding.

---

🏥 MS-DRG Assignment

MDC 01 — Diseases and Disorders of the Nervous System

DRG	Title	Est. Relative Weight*
DRG 056	Degenerative Nervous System Disorders with MCC	~2.23
DRG 057	Degenerative Nervous System Disorders without MCC	~1.30

*Approximate. Verify against IPPS FY2026 Final Rule tables. Degenerative nervous system disorders group to only DRG 056 (MCC) or DRG 057 (no MCC) — there is no DRG 058.

G20.B1 Stage — Active CDI for DRG 056 MCC Triggers

The G20.B1 dyskinesia stage carries elevated risk for MCC-bearing complications compared to G20.A stages. High-value DRG 056 MCC opportunities at every G20.B1 inpatient encounter include:

• Severe dementia coded to F02.Cx tier (e.g., F02.C0, F02.C1) — MCC; most impactful single CDI action
• Aspiration pneumonia (J69.0) — MCC; progressive dysphagia at dyskinesia stage
• Acute respiratory failure (J96.01) — MCC
• Sepsis (A41.9) — MCC
• Protein-calorie malnutrition (E43) — review MCC status; dyskinesia-related caloric expenditure

Without active CDI querying for these comorbidities, G20.B1 inpatient encounters routinely fall to the far lower-weighted DRG 057.

---

🔗 Related ICD-10-CM Codes

G20 Full Motor Complication Matrix

Code	Description	Motor Stage
G20.A1	Without dyskinesia, without mention of fluctuations	Stable; no motor complications
G20.A2	Without dyskinesia, with fluctuations	Wearing-off present; no dyskinesia
G20.B1	With dyskinesia, without mention of fluctuations ← This Code	Dyskinesia present; no wearing-off
G20.B2	With dyskinesia, with fluctuations	Both complications — most advanced stage
G20.C1	Parkinsonism, unspecified	Only when idiopathic vs. secondary undetermined

Drug-Induced Dystonia / Tardive Dyskinesia — Excludes1 from G20.B

Code	Description
G24.01	Drug induced subacute dyskinesia (tardive dyskinesia from neuroleptics — EXCLUDES1 from G20.B; mutually exclusive with G20.B1)
G24.02	Drug induced acute dystonia (acute dystonic reactions — EXCLUDES1 from G20.B)

Mandatory Associated Codes — Dementia (Use Additional Code per Tabular Instruction)

Code	Description	HCC v28
F02.80	Dementia in other diseases, unspecified severity, without disturbance	HCC 127
F02.A0	Dementia in other diseases, mild, without disturbance	HCC 127
F02.B0	Dementia in other diseases, moderate, without disturbance	HCC 126
F02.C0	Dementia in other diseases, severe, without disturbance	HCC 125
F02.81	Dementia in other diseases, unspecified severity, with behavioral disturbance	HCC 127
F02.B1	Dementia in other diseases, moderate, with behavioral disturbance	HCC 126
F02.C1	Dementia in other diseases, severe, with behavioral disturbance	HCC 125

Common Comorbidity Codes at the G20.B1 Stage

Code	Description	Coding Relevance
G90.3	Multi-system degeneration of the autonomic nervous system	Orthostatic hypotension, neurogenic bladder, constipation — autonomic dysfunction; prominent at dyskinesia stage
R13.19	Other dysphagia	Parkinson’s-related dysphagia — increasingly prevalent with disease progression into dyskinesia stage; drives aspiration precautions
J69.0	Pneumonitis due to inhalation of food and vomit (aspiration pneumonia)	MCC; leading cause of death in advanced PD; more likely at G20.B1 than earlier stages
E43	Unspecified severe protein-calorie malnutrition	Dyskinesia produces sustained caloric expenditure through constant involuntary movements; weight loss and malnutrition should be evaluated and coded when documented
E44.0	Moderate protein-calorie malnutrition	Code based on physician documentation of malnutrition severity
G47.52	REM sleep behavior disorder	Prevalent PD comorbidity — often present at dyskinesia stage; can be exacerbated by off-period nocturnal phenomena
F32.9	Major depressive disorder, single episode, unspecified	Neuropsychiatric comorbidity; prevalent in dyskinesia-stage PD
Z96.82	Presence of neurostimulator	Code when DBS is already implanted — supports DBS programming CPT medical necessity
W19.XXXA	Unspecified fall, initial encounter	Falls from dyskinesia-related loss of postural control or from OFF-period freezing; code injury codes when documented

---

🛠️ Commonly Associated CPT Codes (Neurology)

Outpatient and Physician Setting Context

The CPT codes below are associated with the evaluation, management, and advanced therapy treatment of Parkinson’s disease with dyskinesia in outpatient and physician fee schedule settings. In the inpatient setting, ICD-10-PCS procedure codes govern procedural reporting.

CPT Code	Description	Clinical Application
99214	Office or other outpatient visit, established patient, moderate MDC	Neurology follow-up for LID management — amantadine initiation/adjustment, levodopa dosing modification, amantadine ER (GOCOVRI) counseling
99215	Office or other outpatient visit, established patient, high MDC	Complex dyskinesia management — DBS candidacy evaluation, LCIG consideration, polypharmacy adjustment for disabling LID, caregiver burden counseling
99483	Cognitive assessment and care plan services	Formal cognitive assessment for PDD screening at the dyskinesia stage — prevalence of PDD rises at G20.B1 stage; modifier -25 required if same DOS as standard E/M
96132	Neuropsychological testing evaluation; first hour	DBS candidacy evaluation — neuropsychological battery is a standard prerequisite for DBS surgical candidacy; cognitive adequacy is a key DBS eligibility criterion; also used for PDD staging
96133	+Neuropsychological testing evaluation; each additional hour	Add-on; never alone
96116	Neurobehavioral status exam; first hour	Office-based structured cognitive screen — MoCA, MMSE, MDS-UPDRS Part I cognitive; dyskinesia stage requires active dementia surveillance
95983	Electronic analysis of implanted neurostimulator pulse generator/transmitter (DBS), programming; first 15 minutes	DBS programming for G20.B1 patients with existing DBS — GPi stimulation is the preferred DBS target for dyskinesia-predominant PD; STN DBS also effective; parameter adjustment for dyskinesia control
95984	+Electronic analysis of implanted neurostimulator pulse generator/transmitter (DBS), programming; each additional 15 minutes	Add-on; never alone
61885	Insertion or replacement of cranial neurostimulator pulse generator; single electrode array	DBS IPG implantation or replacement — G20.B1 dyskinesia directly supports DBS medical necessity per CMS LCD/NCD criteria
61886	Insertion or replacement of cranial neurostimulator pulse generator; two or more electrode arrays	Bilateral DBS IPG — most common configuration for PD dyskinesia (bilateral GPi most protective against LID; bilateral STN also reduces LID)
96365	Intravenous infusion for therapy; initial, up to 1 hour	Infusion administration for carbidopa-levodopa intestinal gel (LCIG/CLES) or subcutaneous apomorphine in clinic/outpatient settings
96366	+Intravenous infusion; each additional hour	Add-on for additional infusion time; never alone

NCCI Bundling Considerations

NCCI PTP Edits — Verify Before Billing

• 95983 and 95984 bundled into DBS surgical codes (61885/61886) on same DOS — intraoperative programming included in surgical code; do NOT report separately.
• 99215 (complex E/M) and 95983/95984 (DBS programming) same DOS: modifier -25 required on the E/M when it is separately identifiable beyond the programming visit.
• 99483 (cognitive assessment) and standard E/M same DOS: modifier -25 required on the E/M.
• 96132 (neuropsychological testing) and 95983 (DBS programming) same DOS: verify NCCI PTP edit status; documentation must support each as independently performed and separately medically necessary.
• 61885/61886 (IPG implant) and 95983 same DOS: bundled; do NOT report DBS programming on the same day as IPG surgical implantation.
• GPi vs. STN DBS — both targets are Medicare-covered for PD with dyskinesia; document target in the operative note to support appropriate reimbursement.

---

🔬 ICD-10-PCS Crosswalk (Inpatient Procedures)

When G20.B1 is an inpatient diagnosis and a surgical or therapeutic procedure is performed, the following ICD-10-PCS sections and root operations are relevant.

PCS Section	Body System	Root Operation	Clinical Application
0 (Medical & Surgical)	0 (Central Nervous System)	H (Insertion)	00H00MZ — DBS lead placement (open approach, brain — GPi or STN; dyskinesia-predominant PD favors GPi targeting for LID control)
0 (Medical & Surgical)	J (Subcutaneous Tissue)	H (Insertion)	0JH60MZ — DBS IPG implantation (chest subcutaneous tissue)
0 (Medical & Surgical)	D (Gastrointestinal)	H (Insertion)	0DH64UZ — PEG/J tube insertion for LCIG/CLES delivery in dyskinesia-stage patients requiring continuous intrajejunal infusion
0 (Medical & Surgical)	0 (Central Nervous System)	W (Revision)	DBS lead revision or IPG replacement — revision root operation
G (Mental Health)	Z (None)	3 (Psychological Tests)	GZ3ZZZZ — Neuropsychological testing for DBS candidacy assessment in inpatient setting

---

💊 Coding Scenarios and Examples

---

Scenario 1 — Parkinson’s Disease With Dyskinesia, Amantadine Initiation, No Wearing-Off (Outpatient)

Clinical Vignette: A 66-year-old male with Parkinson’s disease on levodopa/carbidopa presents reporting involuntary twisting and writhing movements of his trunk and arms for 3-4 hours after his morning levodopa dose. No wearing-off; levodopa remains effective throughout the dosing interval. Physician documents: “Parkinson’s disease with levodopa-induced peak-dose dyskinesia, no wearing-off.” Amantadine 100 mg BID initiated.

CPT Codes (Outpatient/Physician):

• 99214 — Office visit, established patient, moderate MDC (new complication management, new medication initiation)

ICD-10-CM:

• G20.B1 — Parkinson’s disease with dyskinesia, without mention of fluctuations

Tremor Documentation Does NOT Support G20.B1

If the physician had documented only “Parkinson’s disease with tremor” — without explicitly using the word “dyskinesia” or equivalent — this case would NOT qualify for G20.B1 per AHA Coding Clinic Q1 2024. The coder must not infer dyskinesia from tremor language. Only with explicit documentation of “dyskinesia,” “LID,” or “involuntary movements” is G20.B1 appropriate.

---

Scenario 2 — Parkinson’s Disease With Dyskinesia, DBS Candidacy Evaluation (Outpatient)

Clinical Vignette: A 62-year-old female with disabling levodopa-induced dyskinesia (no wearing-off documented) is referred for DBS candidacy evaluation. Neuropsychological testing ordered to assess cognitive eligibility.

CPT Codes:

• 99215 — Office visit, established patient, high MDC (advanced therapy evaluation, multidisciplinary planning)
• 96132 — Neuropsychological testing evaluation, first hour (DBS candidacy cognitive prerequisite; append modifier -25 on 99215 if same DOS)

ICD-10-CM:

• G20.B1 — Parkinson’s disease with dyskinesia, without mention of fluctuations

GPi vs. STN for Dyskinesia-Predominant PD

When dyskinesia is the primary complaint and fluctuations are absent or minimal (G20.B1 stage), GPi DBS is the preferred surgical target over STN because GPi stimulation provides direct, robust reduction in LID amplitude without the risk of reducing levodopa doses (which STN DBS sometimes allows but can worsen depression/cognition). Documenting the target in the surgical and DBS evaluation documentation is important for audit trail and medical necessity support.

---

Scenario 3 — Parkinson’s Disease With Dyskinesia and Moderate Dementia, DRG 056 (Inpatient)

Clinical Vignette: A 74-year-old male with Parkinson’s disease with dyskinesia (no fluctuations) is admitted for fall with hip fracture. He also has moderate-severity Parkinson’s disease dementia without behavioral disturbance. Documented: “PD with dyskinesia, no wearing-off; moderate dementia due to PD; hip fracture from dyskinesia-related fall.”

Principal Diagnosis:

• G20.B1 — Parkinson’s disease with dyskinesia, without mention of fluctuations (principal — if the dyskinesia/PD management is the primary reason for admission focus; alternatively, the fracture may sequence as principal depending on reason for admission — query)

Additional Diagnoses:

• F02.B0 — Dementia in other diseases, moderate severity, without disturbance (mandatory F02.x pair; moderate dementia — verify CC/MCC status)
• S72.001A — Fracture of unspecified part of neck of right femur, initial encounter (injury code; determines DRG if principal)

Principal Diagnosis Sequencing — Reason for Admission Determines Principal

When a patient with G20.B1 is admitted for a hip fracture, the hip fracture may be the principal diagnosis (if the fracture is the reason for admission and the primary reason resources were expended). G20.B1 sequences as an active comorbidity. Determine principal by applying the UHDDS definition: the condition established after study to be chiefly responsible for occasioning the admission.

---

Scenario 4 — G20.B1 With Existing GPi DBS, Dyskinesia Management Programming Visit (Outpatient)

Clinical Vignette: A 68-year-old female with Parkinson’s disease with dyskinesia (no fluctuations), status post bilateral GPi DBS implantation 1 year ago, presents for programming adjustment targeting persistent LID. Session takes 45 minutes.

CPT Codes:

• 99213 — Office visit, established patient, low MDC; append modifier -25
• 95983 — DBS programming, first 15 minutes
• 95984 — +DBS programming, additional 15 minutes (×2 for the remaining 30 minutes)

ICD-10-CM:

• G20.B1 — Parkinson’s disease with dyskinesia, without mention of fluctuations
• Z96.82 — Presence of neurostimulator (existing DBS device)

---

⚠️ Coding Pitfalls and Tips

	Pitfall or Tip
❌	Never assign G20.B1 based on “tremor” documentation alone — per AHA Coding Clinic Q1 2024, G20.B codes require explicit physician documentation of dyskinesia; rest tremor is a cardinal PD symptom that does NOT map to G20.B
❌	Do not submit the retired bare G20 code — non-billable since FY2024; always use a 5-character G20 subcode
❌	Do not use G20.B1 when wearing-off or OFF episodes are also documented — once fluctuations are present alongside dyskinesia, upgrade to G20.B2
❌	Do not confuse levodopa-induced dyskinesia with tardive dyskinesia — LID in idiopathic PD = G20.B1; neuroleptic-induced tardive dyskinesia = G24.01; these are Excludes 1 — mutually exclusive; if a PD patient on both levodopa and an antipsychotic has involuntary movements, query the physician for attribution before coding
❌	Do not assign G20.B1 for drug-induced parkinsonism — G21.x codes are Excludes1 from all G20 codes
❌	Do not sequence F02.x as principal — Parkinson’s dementia codes are mandatory manifestation codes; G20.B1 always sequences first
✅	Always query: “Does the patient have dyskinesia? Is the dyskinesia levodopa-induced?” — explicit physician documentation is mandatory before G20.B1 can be assigned; the coder’s observation of “shaking” in the chart is not sufficient
✅	Always query: “Are wearing-off or OFF episodes present?” — confirms G20.B1 (no fluctuations) vs. G20.B2 (fluctuations present); determines correct subcode
✅	Query for dementia severity — at the G20.B1 dyskinesia stage, PDD is increasingly prevalent; query mild/moderate/severe for F02.Ax/Bx/Cx HCC tier impact
✅	Code malnutrition when documented — persistent dyskinesia produces significant caloric expenditure; malnutrition is often overlooked but clinically significant at the G20.B stage
✅	G20.B1 is a strong DBS medical necessity support code — dyskinesia is one of the primary DBS indications; ensure the code is in the record before DBS prior authorization submission
✅	GPi DBS target documentation — for dyskinesia-predominant PD at G20.B1 stage, GPi is the preferred target; documenting the target supports appropriate medical necessity and surgical documentation audit trail
✅	Code Z96.82 (presence of neurostimulator) when DBS is implanted at any G20.B1 encounter — supports programming CPT medical necessity and device management documentation

---

📚 Sources

1. CMS/NCHS. ICD-10-CM Official Guidelines for Coding and Reporting, FY2026. Tabular List — G20.B1; G20.B subcategory structure (Excludes1: drug induced dystonia G24.0-); Use additional code instructions.

2. AHA Coding Clinic. Q1 2024 — Coding Parkinson’s Disease: Dyskinesia vs. Tremor. Official guidance: G20.B codes require explicit physician documentation of dyskinesia; tremor alone does not support G20.B assignment.

3. AHA Coding Clinic (via medlearn.com). Coding Update: An Index Change for Parkinson’s Disease. March 2026.

4. UASI Solutions. Parkinson’s Disease Tremor vs. Dyskinesia Coding. April 2025. Clinical and coding distinctions; AHA Coding Clinic Q1 2024 guidance summary.

5. Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 2: Treatment of Levodopa-Induced Dyskinesia. Drugs. Review article.

6. Bhide N, et al. Levodopa-Induced Dyskinesias in Parkinson’s Disease: Clinical Features, Pathophysiology, and Treatment. PMC3483732. Published October 2012. Three LID types; pathophysiology; D1 hypersensitization.

7. Pahwa R, et al. Amantadine Extended-Release Capsules (GOCOVRI) for Levodopa-Induced Dyskinesia. PMC5905495. Published April 2018. FDA approval; EASE LID Phase III trials.

8. PubMed. Meta-analysis of Long-Term Efficacy of Amantadine for Levodopa-Induced Dyskinesia. PubMed 41281192. Published October 2025.

9. CMS. 2026 Medicare Advantage CMS-HCC Model v28 — Final Risk Adjustment Coefficients. HCC 155 (Parkinson’s Disease and Huntington’s Disease).

10. CMS. IPPS Final Rule FY2026 — MS-DRG Definitions Manual v43. MDC 01; DRG 056/057.

11. Boston Scientific. Deep Brain Stimulation 2026 Reimbursement Guide. G20.B1/B2 medical necessity support for DBS; GPi vs. STN targeting for dyskinesia.

12. AMA. CPT Professional Edition 2026. Neurology; DBS programming codes; E/M guidelines.

13. CMS. NCCI Policy Manual for Medicare Services, current version.